Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions
about
Cellular immune responses against hepatitis C virus: the evidence base 2002Prophylactic DNA vaccine for hepatitis C virus (HCV) infection: HCV-specific cytotoxic T lymphocyte induction and protection from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse model.Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses.Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody.Strategies to use immune modulators in therapeutic vaccines against cancerStrategies for designing and optimizing new generation vaccines.Quantitative approaches to computational vaccinology.Possible therapeutic vaccine strategy against human immunodeficiency virus escape from reverse transcriptase inhibitors studied in HLA-A2 transgenic miceHigh frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis BProgress on new vaccine strategies against chronic viral infectionsA push-pull vaccine strategy using Toll-like receptor ligands, IL-15, and blockade of negative regulation to improve the quality and quantity of T cell immune responses.Multiple costimulatory modalities enhance CTL avidity.High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection.Availability of a diversely avid CD8+ T cell repertoire specific for the subdominant HLA-A2-restricted HIV-1 Gag p2419-27 epitopeTARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer.Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients.Identification of HLA-B27-restricted cytotoxic T lymphocyte epitope from carcinoembryonic antigen.Effect of interferon-alpha therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals.Analysis of T cell repertoire in the liver of patients with chronic hepatitis C.Immune responses induced in HHD mice by multiepitope HIV vaccine based on cryptic epitope modification.Molecular diversity of HLA-A*02 in Asian Indians: predominance of A*0211.Cancer vaccine strategies: translation from mice to human clinical trials.Physicochemical explanation of peptide binding to HLA-A*0201 major histocompatibility complex: A three-dimensional quantitative structure-activity relationship study
P2860
Q27480725-A3D13C46-1783-4CCB-AE1F-BBA0E256CD12Q27488288-85EF86B8-0C36-44ED-A61C-664067AF818EQ30449492-6E2DBE5D-28C3-4DFD-B8D2-503E5EE62976Q33581597-98ED005B-A3EC-4E78-BA10-551854F19D0EQ34275601-F8C9C777-0AD8-44B7-9F1E-71678097785EQ34572198-C31EE728-CC4A-4661-B5A7-0A24C12BA096Q34687630-FF0CDF9C-CF0A-4EA0-9A96-F840E78667EBQ35139305-42672A2C-0FDA-4739-BC17-CF6B4D944B64Q35597143-336CB8D9-1BB4-4CB3-A0A2-A9069A632409Q35864857-8943B0B8-EF55-495A-ADA9-1FD5C67855C2Q35871793-6F71C4D4-9BE8-4D3D-81E8-4AE81BC2963BQ35901490-705181B7-656E-4495-8988-A37C911548D4Q36043015-677693C4-AE83-4D40-AE45-5278EEAA0EA5Q36627951-D1DF37A0-1018-4486-B6D7-009E9F4A5C78Q37224581-59C5195A-FDDF-48B6-B357-52619DBF61E0Q37596619-1A59CED3-D049-41AC-90F1-7129BEF55DB3Q40759589-60877E98-7EE3-41E4-87EA-E629C3DB1581Q40761226-9F968006-C05D-46E4-8A8E-E4F2C192B5D0Q42629438-7148664F-A6F5-4C1D-AE9F-281F398AA568Q46087169-FDCCE7DC-89FE-4B9E-BA03-38DEB4887C29Q47889897-8712FDFF-6A35-4CF7-89BF-0BA4CD9C30D2Q48295639-90263F45-BEC4-4ABA-AE18-25271271B268Q57021685-6597E920-3A51-469F-A9DB-A5BCE46C1051
P2860
Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions
description
1998 nî lūn-bûn
@nan
1998 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
name
Enhanced in vitro potency and ...... ary HLA-A2.1 binding positions
@ast
Enhanced in vitro potency and ...... ary HLA-A2.1 binding positions
@en
type
label
Enhanced in vitro potency and ...... ary HLA-A2.1 binding positions
@ast
Enhanced in vitro potency and ...... ary HLA-A2.1 binding positions
@en
prefLabel
Enhanced in vitro potency and ...... ary HLA-A2.1 binding positions
@ast
Enhanced in vitro potency and ...... ary HLA-A2.1 binding positions
@en
P2093
P2860
P356
P1476
Enhanced in vitro potency and ...... ary HLA-A2.1 binding positions
@en
P2093
C D Pendleton
J A Berzofsky
S M Feinstone
T Akatsuka
P2860
P304
P356
10.1172/JCI3714
P407
P577
1998-09-01T00:00:00Z